Zhuoran Wang
Cunzhen Zhang1†
Jianhua Yin
Nan Li- 1Department of Hepatic Surgery I (Ward I) Shanghai Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai, China
- 2Department of Epidemiology, Faculty of Navy Medicine, Navy Medical University, Shanghai, China
- 3Key Laboratory of Biological Defense, Ministry of Education, Shanghai, China
- 4Laboratory of Medical Bioprotection, Navy Medical University, Shanghai, China
- 5The Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China
A Correction on
Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma
By Wang Z, Zhang C, Yin J and Li N (2025) Front. Immunol. 16:1451965. doi: 10.3389/fimmu.2025.1451965
In the published article, there was an error in the author list, and author “Cunzhen Zhang” was erroneously omitted as equal contributing first author. The corrected author list appears below.
“Zhuoran Wang1,2,3,4† Cunzhen Zhang1† Jianhua Yin2,3,4* Nan Li1,5*
†These authors have contributed equally to this work and share first authorship”
The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: hepatocellular carcinoma, TACE, anti-angiogenic therapy, anti-PD-1 antibody, conversion therapy
Citation: Wang Z, Zhang C, Yin J and Li N (2025) Correction: Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma. Front. Immunol. 16:1647890. doi: 10.3389/fimmu.2025.1647890
Received: 16 June 2025; Accepted: 17 June 2025;
Published: 30 June 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Wang, Zhang, Yin and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Nan Li, TGlwYXJpc2xpc2lAYWxpeXVuLmNvbQ==; Jianhua Yin, aGF3a3lqaDE2M0AxNjMuY29t
†These authors have contributed equally to this work and share first authorship